Pay in 4 interest-free payments of $6.69 Learn more
Ships within 48 hours · Estimated delivery Aug 16 - Aug 21
adults found that nearly two thirds of non-diabetic patients (64.8%) discontinued their GLP-1 therapy within one year
It represents the first clinically advanced compound of the triple-incretin agonist class
doi: 10.1016/j.envres.2023.116680 262 XiongW.LiuY.MengY.JiangY.ChenH.LiuR.et al
Fras and colleagues, New England Journal of Medicine, 2021)
Retatrutide is a triple agonist that simultaneously activates GLP-1, GIP, and glucagon receptors
PMID 16399380
US$ 25.47
US$ 21.86
US$ 28.23
